SEC Form 4 · accession 0002143905-26-000003
BlossomHill Therapeutics, Inc. · BLSM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent Paul Liptak
Officer — General Counsel
Period of report
Aug 6, 2026
Accepted (ET)
Aug 10, 2026 · 6:26 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001839970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2026 | P | 2,500 | $15.80 | A | 109,212 | D | |
| Common Stock | Aug 10, 2026 | P | 2,200 | $16.00 | A | 111,412 | D | |
| Common StockF1,F2 | Aug 10, 2026 | C | 22,687 | — | A | 22,687 | I | By Walter T. Liptak Revocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $16.00 | Aug 6, 2026 | A | 46,561 | A | — | Aug 5, 2036 | Common Stock | 46,561 | 46,561 | D |
| Series B Preferred StockF1,F2 | — | Aug 10, 2026 | C | 22,687 | D | — | — | Common Stock | 22,687 | 0 | I |
Explanation of responses
- F1Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
- F2The Reporting Person is a co-beneficiary and co-trustee of the Walter T. Liptak Revocable Trust (the "Trust") and has voting and dispositive power over the securities held by the Trust.
- F31/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.